This MedLibrary.org supplementary page on Granisetron is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
 |
|
|
Granisetron
|
|
| Systematic (IUPAC) name | |
| 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)- indazole-3-carboxamide |
|
| Identifiers | |
| CAS number | |
| ATC code | A04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H24N4O |
| Mol. mass | 312.41 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 60% |
| Protein binding | 65% |
| Metabolism | Hepatic |
| Half life | 3–14 hours |
| Excretion | Renal 11–12%, faecal 38% |
| Therapeutic considerations | |
| Pregnancy cat. |
B1 (Au), |
| Legal status |
S4 (Au), POM (UK), ℞-only (U.S.) |
| Routes | Oral, intravenous |
Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors.
Granisetron was developed by chemists working at the British drug company Beecham around 1988 and is available as a generic. It is produced by Roche Laboratories under the trade name Kytril. The drug was approved in the United Kingdom in 1991 and in United States in 1994 by the FDA.
Granisetron breaks down slowly, staying in the body for a long time. One dose usually lasts 4 to 9 hours and is usually administered once or twice daily. This drug is removed from the body by the liver and kidneys.
Contents |
Indications
- Chemotherapy-induced nausea and vomiting
- 5-HT3 receptor antagonists are the primary drugs used to treat and prevent chemotherapy-induced nausea and vomiting. Many times they are given intravenously about 30 minutes before beginning therapy.
- Post-operative and post-radiation nausea and vomiting
- Is a possible therapy for nausea and vomiting due to acute or chronic medical illness or acute gastroenteritis
- Treatment of Cyclic vomiting syndrome although there are no formal trials to confirm efficacy.
Adverse effects
Granisetron is a well-tolerated drug with few side effects. Headache, dizziness, and constipations are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drug's use. It is broken down by the liver's cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.
External links
References
- Katzung, Bertram G. Basic and Clinical Pharmacology, 9th ed. (2004). ISBN 0-07-141092-9
|
|||||||||||
|
|||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 24 July 2008, at 05:18.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Granisetron".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.